文献速递肿瘤 PET/CT

乳腺癌患者中18F-氟雌二醇肿瘤摄取具有异质性并受转移部位影响

18F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients.
PubMed 文献 · J Nucl Med · 2018-03-30

该研究分析了2009年11月至2014年12月间91例雌激素受体(ER)阳性转移性乳腺癌患者的18F-FES PET/CT,评估ER表达异质性。共识别1617处转移灶,骨转移的18F-FES摄取高于淋巴结和肺转移;聚类分析识别出3个以特定转移部位和影像特征为特点的患者亚组。结论认为18F-FES摄取在肿瘤和正常组织中均存在异质性,并受解剖部位影响。

要点

  • 91例ER阳性转移性乳腺癌患者共1617处转移灶,骨转移占78%、淋巴结15%、肺4%、肝2%。
  • 骨转移18F-FES摄取高于淋巴结转移(几何均值SUVmax 2.61 vs 2.29,P<0.001)和肺转移(2.61 vs 2.23,P=0.021)。
  • 聚类分析识别出3个以特定转移部位和18F-FES PET/CT特征为特点的患者亚组。

核心结论

  • 18F-FES摄取在肿瘤和正常组织中均存在异质性,并受解剖部位影响。
  • 可区分不同摄取模式,可能识别具有生物学相关性的ER阳性转移性乳腺癌患者亚组。

研究设计与样本

  • 分析2009年11月至2014年12月在认证PET/CT系统上对ER阳性转移性乳腺癌患者进行的18F-FES PET检查。
  • SUVmax≥1.5的病灶视为ER阳性,但因肝脏背景信号高而排除肝脏病灶;CT上直径≥10 mm的病灶纳入。
  • 采用多水平线性混合模型评估18F-FES摄取的决定因素,并以每例患者不同影像特征为输入变量进行聚类分析。

主要发现

  • 91例患者中,CT识别1617处转移灶,分布于骨(78%)、淋巴结(15%)、肺(4%)或肝(2%),由CT(11.2%)、PET(56.6%)或两者(32.2%)识别。
  • 患者间中位肿瘤摄取差异大(SUVmax范围0.54-14.21)。
  • 骨转移18F-FES摄取高于淋巴结转移(几何均值SUVmax 2.61 [95%CI 2.31-2.94] vs 2.29 [95%CI 2.00-2.61],P<0.001)。
  • 骨转移18F-FES摄取高于肺转移(几何均值SUVmax 2.61 [95%CI 2.31-2.94] vs 2.23 [95%CI 1.88-2.61],P=0.021)。
  • 周围正常组织SUVmax以骨最高,且因人而异(范围0.7-3.3)。

关键数值与推荐

  • SUVmax≥1.5的病灶视为ER阳性,但肝脏病灶因高背景信号被排除。
  • CT上直径≥10 mm的病灶纳入分析。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heterogeneity of estrogen receptor (ER) expression in breast cancer is recognized. However, knowledge about varying expression across metastases and surrounding normal tissue in patients is scarce. We therefore analyzed 16α-18F-fluoro-17β-estradiol (18F-FES) PET to assess ER expression heterogeneity. Methods:18F-FES PET on accredited PET/CT camera systems performed in patients with ER-positive metastatic breast cancer November 2009-December 2014 was analyzed. Lesions with an SUVmax 1.5 or more were considered ER-positive, but liver lesions were excluded given high background liver signal. CT lesions with a diameter 10 mm or more were included. We used multilevel linear-mixed models to evaluate determinants of 18F-FES uptake. Cluster analysis was performed with different imaging features per patient as input variables. Results: In 91 patients, 1,617 metastases in bone (78%), lymph node (15%), lung (4%), or liver (2%) were identified by CT (11.2%), PET (56.6%), or both (32.2%). Median tumor uptake varied greatly between patients (SUVmax, 0.54-14.21). 18F-FES uptake in bone metastases was higher than in lymph node and lung metastases (geometric mean SUVmax, 2.61 [95% confidence interval (CI), 2.31-2.94] vs. 2.29 [95% CI, 2.00-2.61; P < 0.001] vs. 2.23 [95% CI, 1.88-2.61; P = 0.021]), respectively. Cluster analysis identified 3 subgroups of patients characterized by particular metastatic sites and 18F-FES PET/CT features. SUVmax in surrounding normal tissue, highest in the bones, varied per patient (range, 0.7-3.3). Conclusion:18F-FES uptake is heterogeneous in tumor and normal tissue and influenced by anatomic site. Different patterns can be distinguished, possibly identifying biologically relevant ER-positive metastatic breast cancer patient subgroups.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Nienhuis HH, van Kruchten M, Elias SG, et al. 18F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients. J Nucl Med. 2018. PMID: 29602822. doi:10.2967/jnumed.117.198846

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。